Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 143
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Nature ; 466(7310): 1085-8, 2010 Aug 26.
Article in English | MEDLINE | ID: mdl-20740010

ABSTRACT

Pairs of asteroids sharing similar heliocentric orbits, but not bound together, were found recently. Backward integrations of their orbits indicated that they separated gently with low relative velocities, but did not provide additional insight into their formation mechanism. A previously hypothesized rotational fission process may explain their formation-critical predictions are that the mass ratios are less than about 0.2 and, as the mass ratio approaches this upper limit, the spin period of the larger body becomes long. Here we report photometric observations of a sample of asteroid pairs, revealing that the primaries of pairs with mass ratios much less than 0.2 rotate rapidly, near their critical fission frequency. As the mass ratio approaches 0.2, the primary period grows long. This occurs as the total energy of the system approaches zero, requiring the asteroid pair to extract an increasing fraction of energy from the primary's spin in order to escape. We do not find asteroid pairs with mass ratios larger than 0.2. Rotationally fissioned systems beyond this limit have insufficient energy to disrupt. We conclude that asteroid pairs are formed by the rotational fission of a parent asteroid into a proto-binary system, which subsequently disrupts under its own internal system dynamics soon after formation.

2.
J Exp Med ; 139(3): 785-90, 1974 Mar 01.
Article in English | MEDLINE | ID: mdl-4591179

ABSTRACT

Concentrated medium obtained from cultures of a continuous thymus-derived mouse lymphoma cell line (WEHI-22.1) was found to inhibit a T-cell-dependent (antidonkey red blood cell), but not a T-cell-independent (anti-DNP) immune response in vitro. Passage of such a concentrate through an anti-mouse Ig immunoadsorbent column removed its inhibitory activity. It is suggested that the tumor cell Ig can compete with specific normal T-cell Ig in its collaborative function in immune responses. A similar mechanism may account for anergy associated with some human lymphoid neoplasms.


Subject(s)
Antibody Formation , Immune Tolerance , T-Lymphocytes/immunology , Thymoma/immunology , Thymus Neoplasms/immunology , Animals , Antigen-Antibody Complex , B-Lymphocytes/immunology , Binding Sites, Antibody , Cell Line , Cytotoxicity Tests, Immunologic , Hemolytic Plaque Technique , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Inbred Strains , Neoplasms, Experimental/immunology , Perissodactyla/immunology , Rabbits/immunology , Spleen/immunology
3.
J Exp Med ; 167(2): 353-71, 1988 Feb 01.
Article in English | MEDLINE | ID: mdl-3258007

ABSTRACT

Mice transgenic for a c-myc gene driven by the IgH enhancer (E mu-myc) were shown to almost invariably develop lymphomas, 90% succumbing in the first 5 mo of life. The tumors typically presented as rapidly progressive lymphadenopathy with thymic involvement and were highly malignant by transplantation assay. Morphologically, they were lymphoblastic lymphomas, usually accompanied by lymphoid leukemia and granulocytosis, and were distinct from the tumors that arose much later in 37% of nontransgenic mice of the same (C57BL/6 x SJL)F2 genetic background. Cell-surface markers on 31 E mu-myc tumors identified 52% as pre-B lymphomas, 29% as mixed pre-B and B lymphomas, and 19% as B lymphomas. The tumors appeared to arise at random from a population of pre-B cells expanded by constitutive expression of the myc transgene. A majority of the animals initiated malignancy at the rate of 17% per week. The rate at which the cycling, benign pre-B cells spontaneously convert to malignancy was estimated to about 10(-10) per cell per generation. A transient leukocytosis identified in young E mu-myc mice was developed into a rapid assay for inheritance of the transgene.


Subject(s)
B-Lymphocytes/pathology , Leukemia, Experimental/pathology , Lymphoma/pathology , Mice, Transgenic/genetics , Oncogenes , Animals , Antigens, Neoplasm/classification , Antigens, Surface/classification , B-Lymphocytes/immunology , Disease Models, Animal , Female , Leukemia, Experimental/blood , Leukemia, Experimental/classification , Lymphoma/blood , Lymphoma/classification , Male , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Phenotype , Spleen/pathology
4.
J Exp Med ; 186(9): 1513-22, 1997 Nov 03.
Article in English | MEDLINE | ID: mdl-9348309

ABSTRACT

The mechanisms that establish immune tolerance in immature and mature B cells appear to be distinct. Membrane-bound autoantigen is thought to induce developmental arrest and receptor editing in immature B cells, whereas mature B cells have shortened lifespans when exposed to the same stimulus. In this study, we used Emu-bcl-2-22 transgenic (Tg) mice to test the prediction that enforced expression of the Bcl-2 apoptotic inhibitor in B cells would rescue mature, but not immature, B cells from tolerance induction. To monitor tolerance to the natural membrane autoantigen H-2Kb, we bred 3-83mudelta (anti-Kk,b) Ig Tg mice to H-2(b) mice or to mice expressing transgene-driven Kb in the periphery. In 3-83mudelta/bcl-2 Tg mice, deletion of autoreactive B cells induced by peripheral Kb antigen expression in the liver (MT-Kb Tg) or epithelia (KerIV-Kb Tg), was partly or completely inhibited, respectively. Furthermore, Bcl-2 protected peritoneal B-2 B cells from deletion mediated by acute antigen exposure, but this protection could be overcome by higher antigen dose. In contrast to its ability to block peripheral self-tolerance, Bcl-2 overexpression failed to inhibit central tolerance induced by bone marrow antigen expression, but instead, enhanced the receptor editing process. These studies indicate that apoptosis plays distinct roles in central and peripheral B cell tolerance.


Subject(s)
B-Lymphocyte Subsets/immunology , Clonal Deletion , Proto-Oncogene Proteins c-bcl-2/biosynthesis , Proto-Oncogene Proteins c-bcl-2/physiology , Animals , Antibodies, Anti-Idiotypic/analysis , B-Lymphocyte Subsets/classification , B-Lymphocyte Subsets/metabolism , Cell Differentiation/immunology , Cell Survival/immunology , Dose-Response Relationship, Immunologic , Epithelial Cells/immunology , Gene Rearrangement, B-Lymphocyte, Light Chain , H-2 Antigens/administration & dosage , Hybridomas/transplantation , Immunoglobulin M/analysis , Immunoglobulin kappa-Chains/genetics , Immunoglobulin lambda-Chains/genetics , Injections, Intraperitoneal , Leukocyte Common Antigens/analysis , Liver/cytology , Liver/immunology , Lymphocyte Count , Lymphoid Tissue/cytology , Mice , Mice, Inbred A , Mice, Inbred C3H , Mice, Inbred C57BL , Mice, Knockout , Mice, Transgenic
5.
Science ; 171(3967): 189-91, 1971 Jan 15.
Article in English | MEDLINE | ID: mdl-4395230

ABSTRACT

Mouse lymphoma cells in culture which are killed by adrenal steroids contain specific cortisol receptors that may be involved in the initial events of hormone action. The similarity of these receptors to those in hepatoma tissue culture cells, where adrenal steroids induce tyrosine aminotransferase, suggests that certain aspects of steroid action are similar in the two systems. In three steroid-resistant lymphoma cell populations specific binding was less than in the parent lines, suggesting that conversion to steroid resistance may be associated with changes in specific steroid binding.


Subject(s)
Culture Techniques , Hydrocortisone/pharmacology , Lymphoma , Receptors, Drug , 17-Ketosteroids/pharmacology , Androstanes/pharmacology , Animals , Carcinoma, Hepatocellular/enzymology , Cell Line , Cell Nucleus/metabolism , Cytoplasm/metabolism , Enzyme Induction , Hydroxyprogesterones/pharmacology , Liver Neoplasms , Mice , Testosterone/pharmacology , Tritium , Tyrosine Transaminase/biosynthesis
6.
Endoscopy ; 40(4): 291-5, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18389447

ABSTRACT

AIM: To compare the quality of colonoscopy in the Kent and Medway Strategic Health Authority with national standards and previous audits. METHOD: A prospective 12-month audit of colonoscopy quality as assessed by number of procedures performed, total colonoscopy rates, sedation usage, and complications. Data were collected by 7 endoscopy units on 5905 colonoscopies performed by 62 colonoscopists. The endoscopy unit nurses, as opposed to the colonoscopists, verified that colonoscopy was total. RESULTS: Seven doctors stopped performing colonoscopy during the study period. Thirty-nine of 55 colonoscopists (71 %) achieved total colonoscopy in at least 90 % of cases; 12 (22 %) completed colonoscopy in 80 - 89 % of their cases and 4 (7 %) in 79 % or less of their cases. Seventy-nine percent of colonoscopists used sedation in accordance with British Society of Gastroenterology (BSG) guidelines. Only 22 of 55 (40 %) of colonoscopists performed more than 100 colonoscopies during the 12-month audit period. Reported complications were below expected levels. CONCLUSION: In our study almost one-third of colonoscopists did not achieve colonoscopy completion rates of at least 90%, and less than half performed more than 100 colonoscopies during the 12 month study. Adherence to quality standards appears to be inadequate.


Subject(s)
Colonoscopy/standards , Medical Audit , Quality Assurance, Health Care , Colonoscopy/adverse effects , Female , Humans , Male , Prospective Studies , United Kingdom
7.
Curr Biol ; 11(4): 273-6, 2001 Feb 20.
Article in English | MEDLINE | ID: mdl-11250157

ABSTRACT

The cytoplasmic adaptor protein FADD is an essential component of the death-inducing signaling complexes (DISCs) that assemble when TNF receptor family members, such as Fas, are ligated. FADD inititates the proteolytic cascade that leads to apoptosis by binding to and promoting the autocatalytic activation of caspase-8 [1-4]. Surprisingly, FADD (but not caspase-8) is also required for T cells to proliferate upon their stimulation with mitogens [5-9]. Using transgenic mice expressing a dominant-negative mutant of FADD (FADD-DN), we show that functional FADD is required for T cells to proliferate in response to antigens in vivo as well as to mitogens in culture. The costimulation of wild-type and FADD-DN T cells with mitogens revealed that FADD-DN T cells have a cell-autonomous defect in intracellular signaling. In contrast to another study [6], p53 deficiency did not rescue mitogen-induced proliferation of FADD-DN T cells, and neither did enforced expression of the apoptosis inhibitor Bcl-2. Like wild-type T cells, FADD-DN T cells stimulated with mitogens mobilized intracellular calcium and activated members of the NF-kappaB transcription factor family as well as p38 mitogen-activated protein kinase (MAPK) and p44/42 MAPK. Therefore, FADD must act downstream of or in parallel to these signaling pathways.


Subject(s)
Adaptor Proteins, Signal Transducing , Carrier Proteins/metabolism , Lymphocyte Activation/physiology , Signal Transduction/physiology , T-Lymphocytes/physiology , Animals , Calcium/metabolism , Carrier Proteins/genetics , Cell Division , Fas-Associated Death Domain Protein , Mice , Mice, Transgenic , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3 , Mitogen-Activated Protein Kinases/metabolism , Mutagenesis , NF-kappa B/metabolism , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/metabolism , Tumor Suppressor Protein p53/metabolism , p38 Mitogen-Activated Protein Kinases
8.
Mol Cell Biol ; 9(7): 2798-805, 1989 Jul.
Article in English | MEDLINE | ID: mdl-2789335

ABSTRACT

In chronic myeloid leukemia and some cases of acute lymphoblastic leukemia, a 9;22 chromosome translocation has fused most of the c-abl oncogene to a gene designated bcr. To explore in vivo the biological effects of the chimeric gene, we introduced a facsimile of the translocation product, a bcr-v-abl gene, into the mouse germ line under the control of the immunoglobulin heavy-chain enhancer or a retroviral long terminal repeat. Some transgenic mice bearing either construct developed clonal lymphoid tumors. T lymphomas predominated, but some pre-B lymphomas developed. The transgenes were expressed in the tumors but not detectably in the lymphoid tissues of nontumorous transgenic animals, implying that transcription is activated by a low-frequency somatic event. These results demonstrate that bcr-v-abl is tumorigenic in vivo and provide a new animal model for lymphomagenesis.


Subject(s)
Cell Transformation, Neoplastic , Lymphoma/genetics , Oncogenes , Animals , B-Lymphocytes/immunology , Cloning, Molecular , DNA/biosynthesis , DNA/genetics , Female , Gene Expression Regulation , Genes, Synthetic , Immunoblotting , Lymphoma/immunology , Lymphoma/pathology , Male , Mice , Mice, Transgenic , Phenotype , RNA, Messenger/genetics , T-Lymphocytes/immunology , Translocation, Genetic
9.
J Natl Cancer Inst ; 54(5): 1263-6, 1975 May.
Article in English | MEDLINE | ID: mdl-1168730

ABSTRACT

The uptake of the tumor scanning agent 67-Ga citrate by cultured mouse tumor cells wqs greatly enhanced with small additons of certain sera to the culture medium. This stimulation of uptake was due to a macromolecular serum component, provisionally identified with transferrin. The response under optimum conditions was so great as to suggest that the 67-Ga uptake process depends entirely on the action of transferrin. The same mechanism probably operates in vivo and may help explain interesting features of the tracer's tissue distribution, particularly its tumor affinity.


Subject(s)
Gallium/metabolism , Neoplasms, Experimental/metabolism , Transferrin/pharmacology , Animals , Cell Line , Clone Cells , Gallium Radioisotopes , Mice , Stimulation, Chemical
10.
Waste Manag ; 26(7): 758-68, 2006.
Article in English | MEDLINE | ID: mdl-16531035

ABSTRACT

The use of cement based materials will be widespread in the long-term management of radioactive materials in the United Kingdom. One of the applications could be the Nirex reference vault backfill (NRVB) as an engineered barrier within a deep geological repository. NRVB confers alkaline conditions, which would provide a robust chemical barrier through the control of the solubility of some key radionuclides, enhanced sorption and minimised corrosion of steel containers. An understanding of the dissolution of C-S-H gels in cement under the appropriate conditions (e.g., saline groundwaters) is necessary to demonstrate the expected evolution of the chemistry over time and to provide sufficient cement to buffer the porewater conditions for the required time. A programme of experimental work has been undertaken to investigate C-S-H gel dissolution behaviour in sodium chloride solutions and the effect of calcium/silicon ratio (C/S), temperature and cation type on this behaviour. Reductions in calcium concentration and pH values were observed with samples equilibrated at 45 degrees C compared to those prepared at 25 degrees C. The effect of salt cation type on salt-concentration dependence of the dissolution of C-S-H gels was investigated by the addition of lithium or potassium chloride in place of sodium chloride for gels with a C/S of 1.0 and 1.8. With a C/S of 1.0, similar increases in dissolved calcium concentration with increasing ionic strength were recorded for the different salts. However, at a C/S of 1.8, anomalously high calcium concentrations were observed in the presence of lithium.


Subject(s)
Calcium Compounds/chemistry , Silicates/chemistry , Sodium Chloride/chemistry , Solubility , Water/chemistry
11.
Cancer Res ; 37(10): 3634-8, 1977 Oct.
Article in English | MEDLINE | ID: mdl-561654

ABSTRACT

Radiotracer 67Ga-citrate is used as a tumor-seeking agent in clinical imaging investigations although fundamental reasons for its high uptake in certain malignant lesions remain unexplained. The mechanism by which 67Ga becomes concentrated in tumor cells has been investigated by comparing 67Ga and 59Fe uptake by cultured mouse myeloma cells with particular reference to uptake stimulation by transferrin. Concentrations of human transferrin down to 2 microgram/ml greatly stimulated cellular uptake of both tracers, whereas bovine transferrin proved relatively inactive. The rates of stimulated uptake of both tracers were similar as was their high degree of retention by cells, but their quantitative dependencies on transferrin concentration showed characteristic differences. Pretreatment of human transferrin with saturating amounts of nonradioactive Fe3+ canceled its ability to promote 59Fe uptake, but it had little effect on its promotion of 67Ga uptake. Further increase in the amount of added Fe3+ did cause a progressive depression of 67Ga uptake, but this effect probably relates to the iron distribution in the whole-cell culture system including the fetal calf serum component of cell growth medium. The results suggest that 67Ga and 59Fe reveal different aspects of the interaction of transferrin with cells.


Subject(s)
Gallium Radioisotopes/metabolism , Iron Radioisotopes/metabolism , Multiple Myeloma/metabolism , Transferrin/pharmacology , Animals , Cattle , Cell Line , Dose-Response Relationship, Drug , Humans , Iron/pharmacology , Kinetics , Multiple Myeloma/diagnostic imaging , Neoplasms, Experimental/diagnostic imaging , Neoplasms, Experimental/metabolism , Radionuclide Imaging , Species Specificity
12.
Cancer Res ; 60(5): 1217-20, 2000 Mar 01.
Article in English | MEDLINE | ID: mdl-10728678

ABSTRACT

The tumor suppressor p53 exerts its antioncogenic effects in cells chiefly by regulating their progression through the cell cycle and by inducing cell death. It has been claimed that p53-transduced apoptosis involves the death receptor CD95 (Fas/APO-1). We report that thymocytes from mice lacking functional Fas ligand (gld) show normal sensitivity to apoptosis transduced by p53, and that hepatocytes fromp53-/- mice have normal sensitivity to apoptosis triggered through ligation of CD95. p53 and CD95, therefore, function in independent pathways to cell death in these diverse cell types.


Subject(s)
Apoptosis/genetics , Genes, p53 , Signal Transduction/genetics , fas Receptor/genetics , Animals , Gene Expression Regulation , Mice , Mice, Inbred Strains , Species Specificity , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism , fas Receptor/metabolism
13.
Cancer Res ; 39(2 Pt 1): 538-41, 1979 Feb.
Article in English | MEDLINE | ID: mdl-761229

ABSTRACT

Assays of thirteen cell lines, derived from mouse lymphomas, myelomas, myeloid tumors, and a mastocytoma, for sensitivity to growth inhibition by 1-beta-D-arabinofuranosylcytosine (ara-C) revealed a spectrum between the most and least sensitive which differed 100-fold from each other. An inverse correlation between sensitivity and cellular deoxycytidine 5'-triphosphate (dCTP) content was found, and this suggested that sensitivity of cells might be increased if the dCTP content was lowered during cell exposure to ara-C. Previous work has shown that thymidine treatment of cells lowers their dCTP content, and the effect of thymidine on the sensitivity of six of the cell lines to ara-C was therefore measured. Concentrations of thymidine below those inhibitory to cell growth by themselves caused an increase in ara-C sensitivity by up to 3-fold in 4 cell lines in which thymidine causes a depression in dCTP content but not in 2 myeloid lines in which the dCTP content was found not to be depressed by the same thymidine treatment. The results confirm an important role for dCTP in determining cellular sensitivity to ara-C. The finding that the sensitivity of 2 lymphoma cell lines to ara-C could be increased by concentrations of thymidine in the region of 10 micrometer, which are attainable clinically in humans, suggests that a combination of ara-C with thymidine might be useful in the treatment of some human tumors.


Subject(s)
Cytarabine/administration & dosage , Neoplasms, Experimental/drug therapy , Thymidine/administration & dosage , Cell Line , Deoxycytosine Nucleotides/metabolism , Drug Resistance , Drug Synergism , Drug Therapy, Combination , Neoplasms, Experimental/metabolism
14.
Cancer Res ; 59(7 Suppl): 1685s-1692s, 1999 Apr 01.
Article in English | MEDLINE | ID: mdl-10197581

ABSTRACT

The chromosome translocations typifying Burkitt's lymphoma and follicular lymphoma deregulate very different oncogenes, myc and bcl-2. Transgenic mouse models have illuminated how each contributes to lymphomagenesis. Constitutive myc expression provokes sustained cell proliferation and retards differentiation. However, the resulting expansion in cell number is self-limiting, because the cells remain dependent on cytokines and undergo apoptosis when these become limiting. In contrast, bcl-2 is the prototype of a new class of oncogene that enhances cell survival but does not promote proliferation. Coexpression of these genes leads to the rapid transformation of lymphocytes, probably because each can counter an antioncogenic aspect of the other. Several close homologues of Bcl-2 also enhance cell survival and are thus potential oncogenes; each is essential for maintenance of particular major organs. More distant Bcl-2 relatives instead promote apoptosis and can be regarded as tumor suppressors. For many but not all apoptic signals, the balance between these competing activities determines cell survival. Learning how to adjust the apoptotic threshold in cancer cells should promote development of more effective therapeutic strategies.


Subject(s)
Apoptosis/genetics , Burkitt Lymphoma/genetics , Genes, bcl-2 , Genes, myc , Lymphoma, Follicular/genetics , Animals , Cell Cycle/genetics , Cell Division/genetics , Male , Mice , Mice, Transgenic , Mutation , Spermatogenesis/physiology
15.
Oncogene ; 7(5): 981-6, 1992 May.
Article in English | MEDLINE | ID: mdl-1570158

ABSTRACT

Transgenic mice bearing a mutant, activated N-ras oncogene directed to express within hematopoietic cells by an immunoglobulin enhancer (E mu) sporadically develop T-cell lymphomas and non-lymphoid tumors that may be of macrophage origin. To identify genes that can collaborate with N-ras in hematopoietic neoplasia, Moloney murine leukemia virus was used as an insertional mutagen. Infection of newborn E mu-N-ras mice with the virus greatly accelerated tumorigenesis, and nearly all the tumors proved to be T-cell lymphomas. Their variable surface phenotype (CD4+CD8-, CD4+CD8+ and CD4-CD8-) suggested that cells at several stages of T-cell development were susceptible to tumorigenesis. Southern blot analysis revealed that 68% of the tumors bore a proviral insert 5' to the c-myc gene, while 13% had an insert within the 3' untranslated region of the N-myc gene. Insertion was associated with elevated expression of these genes. Hence, activation of a myc gene appears to be the dominant pathway to tumorigenesis by insertional mutagenesis in lymphoid cells expressing a mutant ras gene. However, since many of the tumors were not transplantable, even the partnership of myc and ras may not suffice for full lymphoid malignancy.


Subject(s)
Cell Transformation, Neoplastic/genetics , Gene Expression Regulation, Viral , Genes, myc/physiology , Genes, ras/physiology , Lymphoma, T-Cell/etiology , Moloney murine leukemia virus , Animals , Blotting, Northern , Blotting, Southern , Chromosome Mapping , Gene Rearrangement , Mice , Mice, Transgenic , Mutagenesis, Insertional , Proto-Oncogene Proteins c-myc/biosynthesis , Proviruses/physiology
16.
Oncogene ; 8(1): 1-9, 1993 Jan.
Article in English | MEDLINE | ID: mdl-8423986

ABSTRACT

To assess the lymphoid tumorigenic potential of bcl-2, mice of five independent strains expressing a bcl-2 transgene in B and/or T cells were monitored for disease up to 12 months of age. Lymphoma prevalence was minimal in the T lineage but significant, although low (3-15%), in the B lineage. The principal types of tumors were plasmacytomas secreting immunoglobulin and novel lymphomas that expressed markers such as Sca-1, CD4, Thy-1, CD34 and CD45(B220), consistent with an origin very early in B-lymphoid development. Rearrangement of the c-myc gene was common in the plasmacytomas, implying a synergistic role for myc and bcl-2 in their etiology, but was not detected in the lymphomas.


Subject(s)
Antibody-Producing Cells/pathology , B-Lymphocytes/pathology , Cell Transformation, Neoplastic , Lymphoma/etiology , Proto-Oncogene Proteins/genetics , Proto-Oncogenes , T-Lymphocytes/pathology , Animals , Gene Rearrangement , Genes, myc , Mice , Mice, Inbred C57BL , Mice, Transgenic , Plasmacytoma/etiology , Proto-Oncogene Proteins c-bcl-2
17.
Oncogene ; 8(11): 3161-4, 1993 Nov.
Article in English | MEDLINE | ID: mdl-8414519

ABSTRACT

The bmi-1 gene was discovered as a frequent target of Moloney virus insertion in virally accelerated B-lymphoid tumors of E mu-myc transgenic mice and hence is thought to collaborate with the myc gene in lymphomagenesis, but its oncogenic potential has not previously been tested directly. To determine whether bmi-1 overexpression can contribute to hematopoietic neoplasia in vivo, strains of transgenic mice were generated in which bmi-1 expression was directed to the lymphoid compartment by a coupled immunoglobulin heavy chain enhancer (E mu). Although the E mu-bmi-1 transgene was expressed in both B and T cells, lymphoid development was not perturbed. Nevertheless, 14% of the mice in the strain with highest expression have developed lymphoma. Unexpectedly, most tumors were of the T-cell lineage, although one case of B lymphoma was observed. Furthermore, cross breeding E mu-bmi-1 and E mu-myc mice established that the bmi-1 transgene markedly accelerated the onset of pre-B and B lymphomas. These results demonstrate directly that bmi-1 can contribute to lymphomagenesis in the T and B cell lineages and collaborate with the myc gene in tumor development.


Subject(s)
Genes, myc , Lymphoma, B-Cell/etiology , Lymphoma, T-Cell/etiology , Nuclear Proteins/genetics , Proto-Oncogene Proteins , Repressor Proteins , Zinc Fingers , Animals , Lymphoma, B-Cell/genetics , Lymphoma, T-Cell/genetics , Mice , Mice, Transgenic , Polycomb Repressive Complex 1
18.
Oncogene ; 18(38): 5268-77, 1999 Sep 20.
Article in English | MEDLINE | ID: mdl-10498879

ABSTRACT

The pathways to lymphoid neoplasia have been explored in a number of transgenic models. Because B lymphoid malignancies often involve translocation of an oncogene (e.g. myc, bcl-2, cyclin D1) to an immunoglobulin locus, resulting in its deregulated expression, the consequences of oncogene overexpression in lymphocytes can be evaluated with transgenes driven by an immunoglobulin regulatory element, such as an enhancer from the IgH locus. Mice bearing such transgenes have provided insight into the preneoplastic state, including alterations in the control of cellular proliferation, differentiation or apoptosis. They have also allowed studies on oncogene cooperation in vivo and the modulating effect of genetic background. Briefly reviewed here are the models studied in the authors' laboratories. Mice bearing myc and bcl-2 transgenes have received most attention but others studied include abl, ras, cyclin D1 and bmi-1 oncogenes. Also discussed is a new transgenic vector that should facilitate transgenic approaches to non-lymphoid leukemias. The vector bears elements from the promoter region of the vav gene, which is expressed almost exclusively in hematopoietic cells. It has proven capable of driving transgene expression throughout the hematopoietic compartment, including progenitor cells and their precursors. This novel vector should aid studies on many aspects of hematopoiesis, including the modeling of leukemogenesis.


Subject(s)
Disease Models, Animal , Genetic Vectors , Hematopoietic Stem Cells/metabolism , Lymphoma/genetics , Animals , Hematopoietic Stem Cells/cytology , Humans , Mice , Mice, Transgenic , Oncogenes/genetics
19.
Oncogene ; 10(5): 1013-7, 1995 Mar 02.
Article in English | MEDLINE | ID: mdl-7898919

ABSTRACT

The cellular growth promoting function of the Myc oncoprotein requires its heterodimerization with the Max protein, but Max can also form complexes that inhibit Myc action. To determine whether max overexpression in vivo is oncogenic and whether it can modulate the action of Myc, we generated transgenic mice in which the max gene was directed to express in lymphoid cells by a linked immunoglobulin heavy chain enhancer (E mu). Expression of the transgene at substantially higher levels than the endogenous max gene did not perturb lymphoid homeostasis in adult animals nor predispose to lymphomagenesis. The numbers of B-lymphoid cells in very young animals were reduced. Moreover, analysis of bi-transgenic E mu-myc/E mu-max mice revealed that max overexpression attenuated the premalignant B-lymphoproliferative state induced by an E mu-myc transgene and reduced the rate of lymphoma onset. These results suggest that elevation of Max expression in vivo inhibits the function of Myc.


Subject(s)
B-Lymphocytes/physiology , DNA-Binding Proteins/genetics , Genes, myc , Lymphoma/etiology , Transcription Factors , Animals , Basic Helix-Loop-Helix Leucine Zipper Transcription Factors , Basic-Leucine Zipper Transcription Factors , Cell Division , Hematopoiesis , Homeostasis , Lymphoma/prevention & control , Mice , Mice, Transgenic
20.
Biochim Biophys Acta ; 561(1): 110-23, 1979 Jan 26.
Article in English | MEDLINE | ID: mdl-570417

ABSTRACT

The effects of various concentrations of thymidine on DNA synthesis and deoxyribonucleoside triphosphate contents of a highly thymidine-sensitive cultured mouse lymphoma cell line (WEHI-7) and a relatively resistant mouse myeloma cell line (HPC-108) have been studied by 32P-labelling techniques. DNA synthesis in the myeloma cells was inhibited by thymidine at concentrations of 10(-3) M or greater, while DNA synthesis in the lymphoma cells was inhibited by concentrations 30-fold lower, consistent with the 25-fold difference between the two cell lines in sensitivity to growth inhibition by thymidine. Thymidine caused marked elevation of the dTTP and dGTP pools, slight elevation or no change in the dATP pool and a marked decrease in the dCTP pool in cells of both lines. The greater resistance of HPC-108 cells to thymidine inhibition was related to the finding that they normally contained a much higher concentration of dCTP than did the WEHI-7 cells. Pool size measurements on thymidine-treated (10(-4) M) cells of an additional seven sensitive lymphoma and six relatively resistant myeloma cell lines indicated that in all 15 lines studied, with one exception, a critical concentration of dCTP of about 32 nmol per ml of cell volume was required for the maintenance of normal rates of DNA synthesis. The dCTP content found normally in the lymphoma cells was only a little above this concentration. Amongst the myeloma lines, three contained similarly low levels of dCTP, but were more resistant to thymidine inhibition probably because of their inefficient production of dTTP from thymidine. Cells of the other four myeloma lines (including HPC-108) normally contained much higher dCTP concentrations. The mechanism of thymidine action was explained by reference to the known allosteric properties of ribonucleotide reductase.


Subject(s)
Deoxyribonucleotides/metabolism , Lymphoma/metabolism , Plasmacytoma/metabolism , Thymidine/pharmacology , Animals , Cell Cycle/drug effects , Cell Division/drug effects , Cell Line , DNA, Neoplasm/biosynthesis , Mice , Neoplasms, Experimental/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL